CSF3 and neutropenia: The use of G‐CSF in our study was more liberal than in usual practice, as our policy at PMH at the time was to try to maintain a lenalidomide dose of 25 mg throughout relapse using growth factor support rather than to reduce the dose if neutropenia occurred 18, 19.